Pembrolizumab + cisplatin + fluorouracil
Checked 2026-09-09
Advanced oesophageal or Siewert type 1 junctional cancer, first line
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Pembrolizumab Monoclonal antibody (anti-PD-1) | 200 mg | IV | D1 | or 400 mg every 6 weeks |
Cisplatin Cytotoxic chemotherapy (platinum) | 80 mg/m² | IV | D1 | |
Fluorouracil infusion Fluoropyrimidine antimetabolite | 800 mg/m² per day | IV | D1-5 (120 h infusion) |
Cycles
chemotherapy 6; pembrolizumab up to 35
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
CAPOX
Adjuvant stage III colon (3 or 6 months), rectal total neoadjuvant therapy, metastatic first line
every 21 days × 4
FOLFIRI
Metastatic colorectal first or second line (with bevacizumab, aflibercept, ramucirumab or an anti-EGFR antibody)
every 14 days
FLOT
Resectable gastric or gastro-oesophageal junction adenocarcinoma, cT2 or higher or node-positive
every 14 days × 4
CROSS chemoradiation
Resectable oesophageal or junctional cancer (T1N1 or T2-3N0-1), before surgery
weekly × 5
Nivolumab + FOLFOX or CAPOX
Unresectable or metastatic HER2-negative gastric, junctional or oesophageal adenocarcinoma, first line (benefit concentrated in PD-L1 CPS 5 or above)
every 14 days